Cederquist has represented Mars, Incorporated, in its acquisition of the AniCura group from Nordic Capital Fund VIII and other sellers.

The AniCura group is one of Europe’s leading providers of high quality veterinary care for companion animals. The group currently operates approximately 200 clinics with a combined turnover of SEK 3.3 bn. and around 4,000 employees. AniCura cares for two million companion animals per year and offers a wide range of high quality medical services covering preventive and basic health care as well as advanced diagnostics, internal medicine, intensive care, surgery and orthopedics. The group also provides rehabilitation, physiotherapy and dietary advice and offers selected pet food and care products.

Mars Petcare is a diverse and growing business with 75,000 Associates in 50+ countries dedicated to one purpose: A BETTER WORLD FOR PETS. With 75 years of experience, the Mars Petcare portfolio of almost 50 brands serves the health and nutrition needs of the world’s pets. Mars Petcare is also a leading veterinary health provider through a network of over 2,000 pet hospitals including BANFIELD™, BLUEPEARL™, PET PARTNERS™, and VCA™ in North America.

The parties have agreed not to disclose financial details. The transaction is subject to customary regulatory approvals.

Cederquist's M&A-team was led by Partners Lars Bärnheim and Carl Johan Deuschl, supported primarily by Associates Magnus Staaf, Anna Lotegen, Sebastian Rosvall and Isabel Cantos. A large team of other specialists also worked on the transaction, including Linnea Härstedt, Björn Sjöberg, Julia Amanda Nilsson, Linnea Eriksson, Michael Boström and Jessica Malhotra (M&A), Babak Morad Bakhti and Oskar Ceréus (Real Estate), Jim Blomström and Saeed Esbati (Regulatory), Robert Stromberg, Jonas Lindskog and Klara Wirén (Employment), Kajsa Morawetz and Oskar Eriksson (Banking and Finance), Kristoffer Molin (Antitrust) and Malin Allard, Martin Gynnerstedt, Jonas Göransson and Pierre Olsson (IP/IT).